Global Atherosclerosis Partnering 2010 to 2017

Publisher Name :
Date: 01-Mar-2017
No. of pages: 100
Inquire Before Buying

"Delivery of this report will take 1-3 days after purchase."

Summary

Provides understanding and access to the atherosclerosis partnering deals and agreements entered into by the worlds leading healthcare companies.

The Global Atherosclerosis Partnering Terms and Agreements since 2010 report provides understanding and access to partnering deals and agreements entered into by the world's leading healthcare companies.

- Trends in partnering deals

- Top deals by value

- Deals listed by company A-Z, industry sector, stage of development, technology type

The report provides understanding and access to the partnering deals and agreements entered into by the world's leading healthcare companies.

The report provides an analysis of partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not.

This data driven report contains multiple links to online copies of actual deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

The initial chapters of this report provide an orientation of partnering trends.

Chapter 1 provides an overview of the trends in partnering since 2010, including a summary of deals by industry sector, stage of development, deal type, and technology type.

Chapter 2 provides a review of the top 10 most active companies in the therapy area, including a comprehensive listing of the deals announced by each company.

Chapter 3 provides a comprehensive directory of partnering deals signed and announced since 2010. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and technology type. Each deal title links via Weblink to an online version of the deal record, and where available the contract document, providing easy access to each contract document on demand.

Chapter 4 provides a listing of partnering deals where a contract document is available alongside the deal record.

Chapters 5 and 6 provide a summary of M&A deals since 2010 where the acquired company is active in the therapy area of interest.

Chapters 7 and 8 provide a summary of financings since 2010 where the financed company is active in the therapy area of interest.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of technologies and products in the therapy area.

Benefits

Global Atherosclerosis Partnering Terms and Agreements since 2010 report provides the reader with the following key benefits:

- In-depth understanding of deal trends since 2010

- Access to headline, upfront, milestone and royalty data

- Comprehensive access to multiple deals entered into by the world's biopharma companies since 2010

- Insight into key deal terms included in contracts, where disclosed

- Understand the key deal terms companies have agreed in deals

- Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Global Atherosclerosis Partnering 2010 to 2017

Table of Contents

Executive Summary

Chapter 1 - Therapypartnering trends in numbers

Partnering in numbers - by year
Partnering in numbers - most active
Partnering in numbers - by industry sector
Partnering in numbers - by deal type
Partnering in numbers - by technology type
Partnering in numbers - by stage of development

Chapter 2 - Most active dealmakers

Chapter 3 - Partnering deals directory

Partnering deals directory - by company A-Z
Partnering deals directory - by deal value
Partnering deals directory - by industry sector
Partnering deals directory - by deal type
Partnering deals directory - by stage of development
Partnering deals directory - by technology area

Chapter 4 - Partnering deals with a contract document

Chapter 5 - SEARCH.THERAPY_AREA M&A in numbers

M&A in numbers - by year

Chapter 6 - M&A deals directory

M&A deals directory - by company A-Z
M&A deals directory - by deal value

Chapter 7 - Financing in numbers

Financing in numbers - by year
Financing in numbers - by financing type

Chapter 8 - Financing deals directory

Financing deals directory - by company A-Z
Financing deals directory - by deal value
Financing deals directory - by financing type

About Wildwood Ventures

Current Partnering
Current Agreements
Recent titles from CurrentPartnering

List of Figures

Figure 1: Partnering frequency by year
Figure 2: Partnering most active
Figure 3: Partnering by industry sector
Figure 4: Partnering by deal type
Figure 5: Partnering by technology area
Figure 6: Partnering by stage of development
Figure 7: M&A frequency by year
Figure 8: Financing frequency by year
Figure 9: Financing by type
  • Top 10 Emerging Technologies
    The World Economic Forum (WEF) and Scientific American lately unveiled the major technological innovation list of the top ten emerging technologies. This list emphasizes on the technological developments which have the supremacy to transform industries, protect the planet, and improve lives. It also presents an opening to discuss any societal, human, economic or environmental jeopardies […]
  • Global Biosimilars Market To Be Led By Novartis by 2020
    Biologics, which are typically inoculated or injected, are formed in living entities, making them more challenging and costly to manufacture than the usual pills contrived from chemicals. Observing that mock-ups are mostly identical to the prototypes has also modelled specific scientific and regulatory tasks. But the US FDA and European supervisors lately have acknowledged new […]
  • Global Thyroid Gland Disorder Treatment Market To Grow Steadily
    The global thyroid gland disorder treatment market was worth US$1.8 billion in 2014 and is projected to reach a market value of US$2.4 billion in 2023 intensifying at a CAGR of 3.1% from 2015 to 2023.  The thyroid gland produces thyroid hormones that control some of the most essential functions in the human body such as stimulating […]
  • Asia Pacific Makeup Market To Grow Owing To Impactful Promotion And Progress Of Distribution Networks
    The Asia Pacific makeup market is one of the most assorted and active markets in the cosmetics industry throughout the world and is projected to grow at a CAGR of 7.1% between 2013 and 2019. The makeup market in Asia Pacific is assessed to be worth US$22.31 billion by 2019. The world-wide market was at an approximation of US$14.76 […]
  • Growing Demand in Emergent Markets To Boost Bakery Ingredients Market
    The baking ingredients market is predictable to grow at a CAGR of 5.2% from 2015 to reach an estimated value of US$ 15.19 billion by 2020. Evolving economies throughout the globe have been displaying demand for bakery ingredients at a greater rate in agreement with the economic growth. Numerous companies have been occupied on refining […]
  • Myocardial Infarction - Pipeline Review, H1 2017
    Published: 31-Mar-2017        Price: US 2000 Onwards        Pages: 307
    Myocardial Infarction - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Myocardial Infarction - Pipeline Review, H1 2017, provides an overview of the Myocardial Infarction (Cardiovascular) pipeline landscape. Myocardial infarction is the irreversible necrosis of heart muscle secondary to prolonged ischemia. Symptoms include pain, fullness, and/or squeezing sensation of the chest, jaw p......
  • Arrhythmias - Pipeline Review, H1 2017
    Published: 15-Mar-2017        Price: US 2000 Onwards        Pages: 47
    Arrhythmias - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Arrhythmias - Pipeline Review, H1 2017, provides an overview of the Arrhythmias (Cardiovascular) pipeline landscape. An arrhythmia is a problem with the rate or rhythm of the heartbeat. During an arrhythmia, the heart can beat too fast, too slow, or with an irregular rhythm. Signs and symptoms include anxiety, weakness, dizz......
  • Atrial Fibrillation - Pipeline Review, H1 2017
    Published: 15-Mar-2017        Price: US 2000 Onwards        Pages: 89
    Atrial Fibrillation - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Atrial Fibrillation - Pipeline Review, H1 2017, provides an overview of the Atrial Fibrillation (Cardiovascular) pipeline landscape. Atrial fibrillation is an irregular and often rapid heart rate that commonly causes poor blood flow to the body. Symptoms include decreased blood pressure, weakness, lightheadedness, co......
  • Congestive Heart Failure (Heart Failure) - Pipeline Review, H1 2017
    Published: 15-Mar-2017        Price: US 2000 Onwards        Pages: 364
    Congestive Heart Failure (Heart Failure) - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Congestive Heart Failure (Heart Failure) - Pipeline Review, H1 2017, provides an overview of the Congestive Heart Failure (Heart Failure) (Cardiovascular) pipeline landscape. Heart failure is also known as congestive heart failure (CHF). CHF is a condition in which the heart is no longer able to ......
  • Myocarditis - Pipeline Review, H1 2017
    Published: 15-Mar-2017        Price: US 2000 Onwards        Pages: 34
    Myocarditis - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Myocarditis - Pipeline Review, H1 2017, provides an overview of the Myocarditis (Cardiovascular) pipeline landscape. Myocarditis is inflammation of the heart muscle. Myocarditis is an uncommon disorder that is usually caused by viral, bacterial, or fungal infections that reach the heart. Symptoms include chest pain, rapid or......
  • Restenosis - Pipeline Review, H1 2017
    Published: 15-Mar-2017        Price: US 2000 Onwards        Pages: 42
    Restenosis - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Restenosis - Pipeline Review, H1 2017, provides an overview of the Restenosis (Cardiovascular) pipeline landscape. Restenosis is re-narrowing of a blood vessel which leads to restricted blood flow. Symptoms include shortness of breath, difficulty walking and chest pain. Risk factors include increasing age, gender, family hist......
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H1 2017
    Published: 08-Mar-2017        Price: US 2000 Onwards        Pages: 207
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H1 2017, provides an overview of the Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular) pipeline landscape.Coronary artery disease (CAD) is the most common type of heart disease. CAD happens when the arteries that supply blood to heart muscle become hardened and narrowed. This is due to the buildup of cholesterol and......
  • Hypotension - Pipeline Review, H1 2017
    Published: 08-Mar-2017        Price: US 2000 Onwards        Pages: 43
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hypotension - Pipeline Review, H1 2017, provides an overview of the Hypotension (Cardiovascular) pipeline landscape.Low blood pressure, or hypotension, occurs when blood pressure during and after each heartbeat is much lower than usual. This means the heart, brain, and other parts of the body do not get enough blood. Symptoms include blurred vision, dizziness, confusion, sleeplessness and weakness. Treatment i......
  • Global Angina Partnering 2010-2017
    Published: 01-Mar-2017        Price: US 1495 Onwards        Pages: 100
    "Delivery of this report will take 1-3 days after purchase." Summary Provides understanding and access to the angina partnering deals and agreements entered into by the worlds leading healthcare companies. The Global Angina Partnering Terms and Agreements since 2010 report provides understanding and access to partnering deals and agreements entered into by the world's leading healthcare companies. - Trends in partnering deals - Top......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs